THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Announces Submission of a Patent Application for N

ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

Announces Submission of a Patent Application for Nasal Administration of Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody,

for Treatment of COVID-19 Patients

York/London, July 31, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"),

a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce

that it has submitted a patent application for the potential use of nasally administered Foralumab, a fully human anti-CD3 monoclonal

antibody (mAb), for the treatment of COVID-19 either alone or in combination with other anti-viral drugs. Recent clinical studies

imply that a combination of anti-inflammatory and anti-viral drugs may be more effective to treat patients at different stages

of COVID-19 disease.

has a worldwide exclusive license for nasal administration of Foralumab and other anti-CD3 mAbs for the treatment of neurodegenerative

and other diseases. The Company previously announced development of a robust formulation and delivery of Foralumab using a nasal

spray device and the successful completion of a Phase 1 trial demonstrating that the treatment was well-tolerated and showed positive

immunomodulatory effects as measured by biomarker analysis (https://www.tizianalifesciences.com/news-item?s=2018-11-28-tiziana-announces-initiation-of-phase-1-clinical-trial-with-nasal-administration-of-foralumab-a-fully-human-anti-cluster-definition-3-monoclonal-antibody-anti-cd3-mab-in-healthy-volunteers).

Tiziana also reported the successful completion of a Phase 1 trial with oral administration of Foralumab, demonstrating that

the treatment was well-tolerated up to a 5 mg dose

(https://www.tizianalifesciences.com/news-item?s=2020-01-09-tiziana-reports-phase-1-clinical-data-demonstrating-oral-treatment-with-foralumab-a-fully-human-anti-cd3-monoclonal-antibody-is-well-tolerated-in-healthy-volunteers).

Importantly, both clinical studies conducted at the Brigham and Women's Hospital and Harvard Medical School, Boston,

MA., indicated that the severe toxicities that are commonly associated with intravenous administration of anti-CD3 mAbs were

not observed with either oral or nasal administration of Foralumab.

administration of Foralumab is a potentially transformative immunomodulatory approach for treating patients with a variety of

human diseases. Results from animal studies, conducted in our laboratory have established that nasal administration of anti-CD3

induces regulatory T cells that suppress inflammation and ameliorate diseases in animal models. This scientific advancement provides

the basis to move forward with clinical development of nasally administered Foralumab in COVID-19 disease," commented Dr.

Weiner, who is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple

Sclerosis Center and Co-Director of the Ann Romney Center for Neurologic Diseases at the Brigham & Women's Hospital.

He continued, "modulating the immune system with nasal anti-CD3 is a first-in-class immunotherapeutic approach to treat

proprietary immunotherapeutic approach using nasal, inhalation and oral administration of mAbs are novel and promising therapies

that stimulate or modulate the immune system so that T regulatory cells (Tregs) are supercharged to inhibit inflammation. The

common underlying concept in these alternative delivery approaches is to strengthen one's own body defense to fight against

inflammation in these diseases. Being a fully human anti-CD3 mAb, we believe Foralumab is most suitable for immunotherapies, as

it does not produce an immune response unlike other humanized anti-CD3 mAbs" commented Dr. Shailubhai, CEO and CSO of Tiziana

person who arranged for the release of this announcement on behalf of the Company was Dr Kunwar Shailubhai, Chief Executive Officer

and Chief Scientific Officer of the Company.

(formerly NI-0401), the only entirely human anti-CD3 mAb, shows reduced release of cytokines after IV administration in patients

with Crohn's disease with decreases in the classic side effects of cytokine release syndrome (CRS) and improves the overall safety

profile of Foralumab. In a humanized mouse model (NOD/SCID IL2 c-/-), it was shown that while targeting the T cell receptor,

orally administered Foralumab modulates immune responses of the T cells, enhances regulatory T-cells (Tregs) and thus provides

therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually

associated with parenteral mAb therapy (Ogura M. et al., 2017). Based on animal studies, the nasal and oral administration of

Foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases in a safe manner by the induction

Tiziana Life Sciences

Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and

development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib,

the Company will be shortly initiating phase 2 studies with orally administered Foralumab for Crohn's Disease and nasally

administered Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb)

in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory

diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis

and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin

6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of

statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts

but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs;

and assumptions. Words such as anticipates,' expects,' intends,' plans,' believes,'

'seeks,' estimates,' and similar expressions are intended to identify forward-looking statements. These

statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors,

some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially

from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security

holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the

date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which

the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking

statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required

by law or by any appropriate regulatory authority.